Un farmaco in fase di valutazione per la malattia di Alzheimer precoce
Lo studio Evoke/Evoke+ è rivolto a persone di età compresa tra 55 e 85 anni con malattia di Alzheimer in fase iniziale.
Dernière mise à jour : 06/11/2023
Language 1
Language 2
Language 3
Privacy on this site
We collect and process your data on this site to better understand how it is used. You can give your consent to all or selected purposes, or you can decline them all. For more information, see our privacy policy.
AnalyticsWe'll collect information about your visit to our site. It helps us understand how the site is used – what's working, what might be broken and what we should improve.
